Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Growth in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 5,100,000 shares, a growth of 7.8% from the October 15th total of 4,730,000 shares. Currently, 25.2% of the shares of the stock are sold short. Based on an average daily volume of 191,600 shares, the days-to-cover ratio is currently 26.6 days.

Analysts Set New Price Targets

Several analysts have weighed in on DNTH shares. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Wedbush decreased their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. Oppenheimer boosted their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Robert W. Baird began coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They set an “outperform” rating and a $58.00 price target on the stock. Finally, Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $46.43.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNTH. Quest Partners LLC increased its stake in shares of Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares during the last quarter. SG Americas Securities LLC bought a new stake in Dianthus Therapeutics in the second quarter valued at approximately $112,000. The Manufacturers Life Insurance Company bought a new stake in Dianthus Therapeutics in the second quarter valued at approximately $236,000. Fred Alger Management LLC raised its holdings in Dianthus Therapeutics by 52.5% in the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after purchasing an additional 3,316 shares during the period. Finally, WINTON GROUP Ltd bought a new position in shares of Dianthus Therapeutics during the second quarter worth $265,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH opened at $23.60 on Tuesday. Dianthus Therapeutics has a fifty-two week low of $6.58 and a fifty-two week high of $33.77. The firm has a market capitalization of $698.56 million, a P/E ratio of -9.44 and a beta of 1.84. The company’s 50 day simple moving average is $27.50 and its 200 day simple moving average is $26.70.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Sell-side analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.